Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.64 |
| ▸ | TK1 | P04183 | 5/20 | 0.53 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.52 |
| ▸ | ALB | P02768 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11986879 | 0.94 | RNASE1 (0.61) | RNASE1TK1ABCG2ABCB1 | |
| SCHEMBL31227958 | 0.94 | RNASE1 (0.61) | RNASE1TK1ABCG2ABCB1 | |
| SCHEMBL4278972 | 0.94 | RNASE1 (0.61) | RNASE1TK1ABCG2ABCB1 | |
| SCHEMBL13948025 | 0.94 | RNASE1 (0.61) | RNASE1TK1ABCG2ABCB1 | |
| SCHEMBL32668971 | 0.94 | RNASE1 (0.61) | RNASE1TK1ABCG2ABCB1 | |
| SCHEMBL12969271 | 0.94 | RNASE1 (0.61) | RNASE1TK1ABCG2ABCB1 | |
| SCHEMBL1827369 | 0.94 | RNASE1 (0.61) | RNASE1TK1ABCG2ABCB1 | |
| SCHEMBL4278968 | 0.94 | RNASE1 (0.61) | RNASE1TK1ABCG2ABCB1 | |
| SCHEMBL22143532 | 0.94 | RNASE1 (0.61) | RNASE1TK1ABCG2ABCB1 | |
| SCHEMBL2327879 | 0.94 | RNASE1 (0.61) | RNASE1TK1ABCG2ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612197-B2 | Reacting a nucleophil with OH group with an electrophil to form an adduct, reacting adduct with a reagent selected from oxidizing, sulfurizing or selenizing agents to produce hydroxy protected oligonucleotide, heating to deprotect hydroxy protecting group such as 2-(2-pyridyl)aminoethoxycarbonyl | The United States of America as repesented by the Secretary of the Department of Health and Human Services (US) | 2009-11-03 | — | — | US | disclosed |
| US-20060281911-A1 | Thermolabile hydroxyl protecting groups and methods of use | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH (US) | 2006-12-14 | — | — | US | disclosed |
| WO-2004101582-A2 | THERMOLABILE HYDROXYL PROTECTING GROUPS AND METHODS OF USE | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281911-A1 | Thermolabile hydroxyl protecting groups and methods of use | ADH1A, CYP2E1, ADH1C | RNASE1 552/4885TK1 1425/4885ABCG2 2444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.